| 1 |
Greening DW, Xu R, Ale A, Hagemeyer CE, Chen W. Extracellular vesicles as next generation immunotherapeutics. Semin Cancer Biol 2023;90:73-100. [PMID: 36773820 DOI: 10.1016/j.semcancer.2023.02.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Nieland L, Mahjoum S, Grandell E, Breyne K, Breakefield XO. Engineered EVs designed to target diseases of the CNS. J Control Release 2023;356:493-506. [PMID: 36907561 DOI: 10.1016/j.jconrel.2023.03.009] [Reference Citation Analysis]
|
| 3 |
Wang S, Shi Y. Exosomes Derived from Immune Cells: The New Role of Tumor Immune Microenvironment and Tumor Therapy. Int J Nanomedicine 2022;17:6527-50. [PMID: 36575698 DOI: 10.2147/IJN.S388604] [Reference Citation Analysis]
|
| 4 |
Wang NH, Lei Z, Yang HN, Tang Z, Yang MQ, Wang Y, Sui JD, Wu YZ. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Ann Transl Med 2022;10:1406. [PMID: 36660640 DOI: 10.21037/atm-22-6049] [Reference Citation Analysis]
|
| 5 |
Matsuzaka Y, Yashiro R. Molecular Docking and Intracellular Translocation of Extracellular Vesicles for Efficient Drug Delivery. IJMS 2022;23:12971. [DOI: 10.3390/ijms232112971] [Reference Citation Analysis]
|
| 6 |
Dank M, Mühl D, Herold M, Hornyák L, Szasz AM, Herold Z. Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer? JCM 2022;11:4815. [DOI: 10.3390/jcm11164815] [Reference Citation Analysis]
|
| 7 |
Moloudizargari M, Asghari MH, Jørgensen MM, Reiter RJ, Kabelitz D. Editorial: Extracellular vesicles in cancer immunosurveillance. Front Immunol 2022;13:993967. [DOI: 10.3389/fimmu.2022.993967] [Reference Citation Analysis]
|
| 8 |
Zhang E, Phan P, Zhao Z. Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Haag F, Manikkam A, Kraft D, Bär C, Wilke V, Nowak AJ, Bertrand J, Omari J, Pech M, Gylstorff S, Relja B. Selective Internal Radiotherapy Changes the Immune Profiles of Extracellular Vesicles and Their Immune Origin in Patients with Inoperable Cholangiocarcinoma. Cells 2022;11. [PMID: 35954154 DOI: 10.3390/cells11152309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Tang Q, Yang S, He G, Zheng H, Zhang S, Liu J, Wei S, Fan Q, Peng X, Li X, Zhang D, Yang L, Li H. Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. Cancer Lett 2022;:215823. [PMID: 35835409 DOI: 10.1016/j.canlet.2022.215823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Chen X, Jia M, Ji J, Zhao Z, Zhao Y. Exosome-Derived Non-Coding RNAs in the Tumor Microenvironment of Colorectal Cancer: Possible Functions, Mechanisms and Clinical Applications. Front Oncol 2022;12:887532. [PMID: 35646623 DOI: 10.3389/fonc.2022.887532] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 12 |
Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 13 |
Fridman ES, Ginini L, Gil Z. The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment. Cells 2022;11:1433. [PMID: 35563739 DOI: 10.3390/cells11091433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
